EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine

Amy Ziemba, Eugene Hayes, Burgess B Freeman, Tao Ye, Giuseppe Pizzorno

Chemotherapy Research and Practice · 2011

DOI: 10.1155/2011/965826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy Research and Practice, 2011. Verfasst von Amy Ziemba und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nevada Cancer Institute, One Breakthough Way, Las Vegas, NV 89135, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelodysplastic syndromes (MDSs) represent a group of incurable stem-cell malignancies which are predominantly treated by supportive care. Epigenetic silencing through promoter methylation of a number of genes is present in poor-risk subtypes of MDS and often predicts transformation to acute myelogenous leukemia (AML). Azacitidine and decitabine, two FDA-approved DNA methyltransferase (DNMT) inhibitors, are able to improve overall response although their oral bioavailability complicates their clinical use. This study evaluated -triacetyl-5-azacitidine (TAC) as a potential prodrug for azacitidine. The prodrug demonstrated significant pharmacokinetic improvements in bioavailability, solubility, and stability over the parent compound. In vivo analyses indicated a lack of general toxicity coupled with significantly improved survival. Pharmacodynamic analyses confirmed its ability to suppress global methylation in vivo. These data indicate that esterified nucleoside derivatives may be effective prodrugs for azacitidine and encourages further investigation of TAC into its metabolism, activity, and possible clinical evaluation.

Autor:innen und Institutionen

  • Nevada Cancer Institute, One Breakthough Way, Las Vegas, NV 89135, USA.

Zitieren

APA

Ziemba, A., Hayes, E., Freeman, B. B., Ye, T., & Pizzorno, G. (2011). Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine. Chemotherapy Research and Practice. https://doi.org/10.1155/2011/965826

Vancouver

Ziemba A, Hayes E, Freeman BB, Ye T, Pizzorno G. Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine. Chemotherapy Research and Practice. 2011. doi:10.1155/2011/965826

BibTeX
@article{Ziemba2011,
  author = {Ziemba, Amy and Hayes, Eugene and Freeman, Burgess B and Ye, Tao and Pizzorno, Giuseppe},
  title = {Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine},
  journal = {Chemotherapy Research and Practice},
  year = {2011},
  doi = {10.1155/2011/965826}
}
Kostenlos starten →